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Early activation of myogenesis in the somite depends on signals from surrounding tissues. Canonical β-catenin dependent Wnt signalling
preferentially activates Myf5. We now show, in explant experiments with presomitic mesoderm, that the expression of another myogenic
determination factor, MyoD, depends on non-canonical Wnt signalling, probably emanating from the dorsal ectoderm. Inhibitors of PKC block
MyoD expression, indicating that the intracellular Wnt pathway depends on this kinase. In the absence of Myf5 and Mrf4, this activation is only
minorily affected and we identify Pax3 as the transcriptional mediator responsible for MyoD expression. When embryos expressing a
constitutively active form of Pax3, PAX3–FKHR, are used for these studies in the presence of PKC inhibitors, MyoD expression is not affected,
suggesting that Wnt signalling acts on the transcriptional activity of Pax3.
© 2007 Elsevier Inc. All rights reserved.Keywords: Non-canonical Wnt signalling; PKC; MyoD; Pax3; Onset of myogenesis; Mouse embryoIntroduction
Skeletal myogenesis is initiated in the paraxial mesoderm in
response to signalling molecules produced by neighbouring
tissues, such as the neural tube, and the notochord or the dorsal
ectoderm, leading to the activation of myogenic regulatory
factor genes such as Myf5 and MyoD (Tajbakhsh et al., 1998).
These signalling molecules include members of the Wnts, Bmp
and Shh families. Wnts constitute a large gene family, related to
Drosophila wingless, and encoding secreted glycoproteins
which are implicated in a multitude of developmental processes.
Wnts bind to Frizzled (Fz) receptors on target cells to activate
different signalling pathways, on the basis of which they can be
divided into two main classes. Some Wnts, such as Wnt1,⁎ Corresponding author. Stem Cell Research Institute, H. San Raffaele
Scientific Institute, Via Olgettina 58, 20132, Milan, Italy. Fax: +39 0226434621.
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doi:10.1016/j.ydbio.2007.01.006Wnt3a and Wnt8, activate the so-called canonical pathway,
leading, through inactivation of glycogen synthase kinase
(GSK-β3), to stabilization and subsequent nuclear translocation
of β-catenin which then activates TCF/LEF1 (T-cell factor/
lymphocyte enhancer factor) transcription factors and induces
Wnt-responsive genes (Eastman and Grosschedl, 1999; Filali et
al., 2002; Pilon et al., 2006; Reya et al., 2003). In contrast, other
Wnts, such as Wnt5a, have been described to activate other
signalling pathways in different cell systems, such as the planar
cell polarity-like pathway and theWnt/Ca2+ pathway, through a
β-catenin-independent noncanonical intracellular cascade
involving protein kinase C (PKC) and c-Jun NH2-terminal
kinase (JNK) (Jin et al., 2005; Sheldahl et al., 1999). Wnt7a and
Wnt11, on the other hand have been shown to act both through a
canonical and a non-canonical pathway (Adamska et al., 2004,
2005; Kengaku et al., 1998; Pandur et al., 2002a; Tao et al.,
2005) in different cell systems. It would appear that the same
Wnt can signal through different signalling pathways and that
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regulate the cellular readout of Wnt signalling (Pandur et al.,
2002b).
PKA may be another player in these complex intracellular
signalling pathways leading to myogenesis. It has been
demonstrated that adenyl cyclase signalling via PKA and its
target transcription factor, CREB, are required for Wnt-directed
myogenic gene expression (Chen et al., 2005). Wnt proteins can
also stimulate CREB-mediated transcription, providing evi-
dence for a Wnt signalling pathway involving PKA and CREB.
However it is not clear whether and how this PKA dependent
Wnt signalling could affect specifically MyoD or Myf5 or both,
and whether there is cross-talk between this pathway and the β-
catenin pathway.
We previously showed that Wnt1 and Wnt3a, produced in
the dorsal neural tube, adjacent to the site of epaxial
myogenesis, preferentially activate Myf5 whereas Wnt7a and
Wnt6, produced in the dorsal ectoderm, preferentially induce
activation of MyoD (Cossu et al., 1996; Tajbakhsh et al., 1998),
which can occur in the absence of Myf5/Mrf4. Recently we
showed direct activation of a Myf5 regulatory element that
targets early epaxial myogenesis, by activated β-catenin
(Borello et al., 2006). Since Wnt7a may, in some contexts, act
through a non-canonical pathway, we decided to investigate
whether the Myf5 independent activation of MyoD, first
observed during hypaxial myogenesis, was occurring in a β-
catenin independent way.
By using a combination of genetic and pharmacological
tools, we demonstrate here that in explants of pre-somitic
mesoderm (PSM), MyoD expression can be activated in the
absence of functional β-catenin and of Myf5, indicating that
myogenesis can be induced through a PKC dependent, β-
catenin independent, pathway. We also demonstrate that Pax3 is
required in this pathway and that its transcriptional activity
depends on PKC.Materials and methods
Mouse lines
Generation and genotyping of the Pax3GFP/+, Pax3PAX3–FKHR–IRESnlacZ/+,
P34, Myf5LacZ/LacZ and Myf5LoxP/LoxP have been described elsewhere (Kassar-
Duchossoy et al., 2004; Relaix et al., 2003, 2004) β-cateninfloxdel/floxedmice were
obtained by intercrossing β-cateninfloxdel/+ with β-cateninfloxed/floxed mice (Brault
et al., 2001; Lallemand et al., 1998).
Organ and cell culture and infection
For most experiments, embryos ranging in age from 20 to 25 somites
(E9.5 days) were isolated in PBS. The tissues were then digested with 0.25%
pancreatin–0.1% trypsin for 5 min at 4 °C. After the enzymatic digestion, the
various tissues were mechanically separated according to the experimental
scheme and then cultured in complete medium (see below). Unless otherwise
indicated, presomitic mesoderm (PSM) refers to paraxial mesoderm immedi-
ately posterior to the most newly formed somite, alone with no associated
structures. In some experiments dorsal ectoderm was left associated with the
PSM and this is specified in the text.
All cultures were grown in RPMI medium (SIGMA) supplemented
with 15% fetal calf serum (GIBCO), 300 mM β-mercaptoethanol and
50 mg/ml gentamycin. In experiments where co-culture with Wnt expres-sing cells was required, the tissue fragment were seeded onto a layer of
3T3 cells expressing Wnt1 or Wnt7a as previously described (Borello et
al., 1999).
3 h after plating, inhibitors were added to the culture, at the following
concentrations: Calphostin C (1 μM), Bisindolylmaleimide I (500 nM), the JNK
inhibitor SP600125 w(10 μM), rottlerin (5 μM), Go6976 (5 nM), (CALBIO-
CHEM), KIC1-1 (Classical PKC Inhibitor), KIE1-1 (Epsilon PKC Inhibitor
peptide), KIET1-1 (Eta PKC Inhibitor peptide), KIBI31-1 (BetaI PKC Inhibitor
peptide), KIBII31-1 (BetaII PKC Inhibitor peptide), KIG31-1, (Gamma PKC
Inhibitor peptide) (1 μM) (KAIPHARMA). Unless otherwise indicated,
inhibitors were added every 24 h, the inhibitor peptides every 8 h, and the
culture was carried out for a total of 60 h to allow the beginning of myogenic
differentiation.
The CRE lentiviral vector (in pRRLsin.PPT.CMV.NTRiresGFPpre) was
generated and prepared as described previously (Borello et al., 2006). The
final MOI was 5×107 PFU/ml. After 6 h culture, the explants were infected
with a MOI of 100 in RPMI/15%FCS overnight. The following day the
medium was changed. The explants were cultured for a total of 3 days. To
test for the correct excision of the floxed β-catenin, PCR was performed on
genomic DNA from the explant at different times, with the following
primers:
RM41: AAG GTA GAG TGATGA AAG TTG TT;
RM42: CAC CAT GTC CTC TGT CTA TCC;
RM43: TAC ACT ATT GAATCA CAG GGA CTT.
In addition RT-PCR was performed on RNA extracted from the explants at
different times using the following primers:
Cre Fw: GACCAAGTGACAGCAATGCTGTTTCA;
Cre rev: CACCAGCTTGCATGATCTCCGGTATT;
β-catenin Fw: GTGCAATTCCTGAGCTGACA;
β-catenin rev: CTTAAAGATGGCCAGCAAGC-3′;
GAPDH Fw: TGAAGGTCGGAGTCAACGGATTTGGT;
GAPDH Rev: CATGTGGGCCATGAGGTCCACCAC.
At the times indicated, cultures were fixed and immunofluorescence was
performed using different antibodies.
Immunofluorescence
Immunofluorescence on cultured explants was carried out as described
(Brunelli et al., 2004) using the following antibodies and dilutions: goat
polyclonal anti β-galactosidase (Biogenesis) antibody (1:350); MF20 anti-
sarcomeric myosin monoclonal antibody (DHSB) (1:4); mouse monoclonal
anti-MyoD antibody (DAKO) (1:200); rabbit polyclonal anti Myf5 antibody
(Santa Cruz) (1:300); rabbit polyclonal anti-sarcomeric myosin antibody
(Cusella-De Angelis et al., 1994) (1:500); anti-GFP rabbit polyclonal antibody
(Molecular Probes)(1:300); anti-GFP monoclonal antibody (Molecular Probes)
(1:200). Primary antibodies were detected by appropriate secondary antibodies
(Molecular Probes), conjugated with either Alexa 594, or Alex 498, for
fluorescence detection.
Protein extraction and Western analysis
Embryos or cultured explants were washed in PBS and solubilised in the
following lysis buffer: 20 mMMOPS, pH 7. 2 mMEGTA, 5 mMEDTA, 30 mM
sodium fluoride, 40 mM β-glycerophosphate, pH 7.2, 20 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl-
fluoride, 3 mM benzamidine, 5 μM pepstatin A, 10 μM leupeptin, 0.5% Nonidet
P-40. The protein extracts (1 mg/ml) were boiled for 4 min at 100 °C in SDS-
PAGE Sample Buffer (31.25 mM Tris–HCl (pH 6.8), 1% SDS (w/v), 12.5%
glycerol (v/v), 0.02% bromophenol blue (w/v), and 1.25% β-mercaptoethanol).
Alternatively PSM was solubilised in the same lysis buffer minus sodium
orthovanadate and with 1 mMEDTA, then incubated for 60 min at 37 °C with 20
units of Calf Intestinal Alkaline Phosphatase (CIP), then boiled in the sample
buffer.
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KINETWORKS™ PHOSPHO-SITE SCREEN 4.1, or loaded onto 10% sodium
dodecyl sulfate-polyacrylamide gels for Western analysis. After electrophoresis,
polypeptides were electrophoretically transferred to nitro-cellulose filters
(Schleicher and Schuell, Dassel, Germany) and antigens revealed by the
following primary monoclonal antibodies: mouse anti-PKCα, PKCβ, PKCδ,
PKCε, PKCη, PKCγ, PKCλ (BD-Transduction Laboratories)(Lexington, KY,
USA), mouse anti-PAX3 mAb (Hybridoma Bank), anti-Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) mAb from Biogenesis (Poole, England).
Primary antibodies were detected by chemiluminescence with appropriate
horseradish peroxidase-conjugated secondary antibodies (Biorad, Hercules, CA,
USA).
Image acquisition and manipulation
Images in fluorescence were taken on the Nikon microscope Eclipse E600
(lenses Plan Fuor: 4×/013, 10×/0.33, 20×/0.50, 40×/0.75). All images have been
acquired using the NIKON digital camera DXM1200, and the acquisition
software NIKON ACT-1. Images were than assembled in panels using Adobe
Photoshop 7.0.Fig. 1. MyoD activation can occur independently of β-catenin. (A–H) Immunofluore
presence of dorsal ectoderm (DE) (A–B, E–F) or neural tube (NT) (C–D, G–H), and
D) or a control vector expressing GFP only (GFP) (E–H), using antibodies specific
number (n) of Myf5 or MyoD expressing cells in explant cultures under the variou
averaged. Single and triple asterisks represent P<0.05 and P<0.001 respectively vs.
explants, showing the excision of β-catenin in the presence of the lentiviral vector ex
catenin allele; del, deleted β-catenin allele. (K) RT-PCR on total RNA extracted from
recombinase, β-catenin and GAPDH. Scale bar in panel A, 100 μm.Statistical analysis
The results are expressed as means±S.E.M.; n represents the number of
individual experiments. Statistical analysis was carried out using the ANOVA
one way analysis of variance. Asterisks in the figure panels refer to statistical
probabilities vs. untreated controls. Statistical probability values (P) of less than
0.05 were considered significant.
Results
MyoD activation can occur independently of β-catenin
We investigated the requirement of β-catenin for MyoD or
Myf5 expression, by analyzing this in a β-catenin null genetic
background. We infected presomitic mesoderm explants (PSM),
dissected from embryonic day (E) 9.5 β-cateninfloxdel/floxed
embryos (Brault et al., 2001), with a lentiviral vector
expressing CRE recombinase (Cre) (Figs. 1E–H, I) or ascence on PSM explants dissected from E 9.5 β-cateninfloxdel/floxed embryos in the
infected with a lentiviral vector expressing CRE recombinase and GFP (Cre) (A–
for GFP (green) together with MyoD or Myf5 (red). (I) Histogram showing the
s conditions. Independent experiments (n=6) were performed in triplicate and
control (C). Bars represent S.E.M. (J) PCR on genomic DNA extracted from the
pressing Cre, at different times after infection (18, 30 and 40 h). Flox, floxed β-
the explant at different times after lentiviral infection, showing expression of Cre
Fig. 2. PKC inhibitors abrogate dorsal ectoderm dependent myogenesis in PSM
explants. (A–L) Immunofluorescence on PSM explants from E9.5 embryos left
to differentiate on a feeder layer of Wnt7a (A–F) or Wnt1 (G–L) expressing
cells, in the presence of the PKC inhibitor Bisindolylmaleimide I (0.5 μM) (B, E,
H, K) or the JNK inhibitor SP600125 (10 μm) (C, F, I, L) or DMSO as a control
(A, D, G, J) using antibodies specific for Myosin Heavy Chain, MyoD or Myf5,
colour coded as indicated. (M) Summary of the experiments shown as examples
in panels A–L, together with experiments in which explants were cultured with
the neural tube or dorsal ectoderm. Histograms representing the number of cells
expressing Myosin Heavy Chain, MyoD or Myf5, in the different culture
conditions are shown. Independent experiments (n=6) were performed in
triplicate and averaged. Single and double asterisks represent P<0.01 and
P<0.001 respectively vs. control (C). Bars represent S.E.M. DE, dorsal
ectoderm; NT, neural tube; C, control (with DMSO alone); Bis, Bisindolylma-
leimide I (0.5 μM); CalC, Calphostin C (1 μM); JNK, SP600125 (10 μM). Scale
bar in panel A, 100 μm.
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ectoderm (DE) or neural tube (NT) (Figs. 1A–B). Cre-
mediated deletion of β-catenin, verified by PCR and RT-PCR
(Figs. 1J–K), leads to a strong decrease in Myf5 expression in
the PSM, induced by signals from the neural tube (Figs. 1H, I),
in comparison with a culture infected with the control lentiviral
vector (Figs. 1D, I)) as described previously (Borello et al.,
2006). Under these conditions MyoD expression is also
reduced (Figs. 1C, G, I). On the other hand, MyoD expression,
induced in the presence of dorsal ectoderm, was not affected
(Figs. 1A, E, I). [Suppl. Fig. 1 provides images of the DAPI
staining corresponding to panels A–H in Fig. 1]. These data
suggest that β-catenin signalling plays an important role in
neural tube mediated expression of these myogenic determina-
tion factors in the PSM, but not in that mediated by dorsal
ectoderm, indicating that the latter depends on a β-catenin
independent pathway.
PKC inhibitors abrogate dorsal ectoderm or Wnt7a dependent
myogenesis in the PSM
Two non-canonical Wnt pathways have been described,
namely the Wnt/Ca(2+) pathway, which goes through protein
kinase C (PKC), and the Wnt/PCP pathway involving Rho/Rac
small GTPases and Jun N-terminal kinase (JNK) classes of
transduction molecules. We examined whether the expression
of MyoD, which depends on dorsal ectoderm and can be
induced by Wnt7a (Tajbakhsh et al., 1998), requires the
presence of functional PKC or JNK activities.
PSM was dissected free of dorsal ectoderm or neural tube,
from E9.5 embryos and cocultured on a layer of 3T3 cells
expressing either Wnt7a (Figs. 2A–F and Suppl. Figs. 2A–F for
DAPI staining) or Wnt1 (Figs. 2G–L and Suppl. Figs. 2G–L for
DAPI staining), in the presence or absence of PKC inhibitors,
Calphostin C or Bisindolylmaleimide or the JNK inhibitor,
SP600125. The explants were left to differentiate for 3 days
(drugs were added 3 h after plating and then every 24 h), before
examination of Myf5 or MyoD expression. As previously
described (Tajbakhsh et al., 1998), Wnt1 preferentially activates
Myf5 (Figs. 2G, J, M) and Wnt7a, MyoD (Figs. 2A, D, M),
leading to myogenesis, as seen by the appearance of Myosin
Heavy Chain expressing cells (Figs. 2A, G, M). In the presence
of PKC inhibitors, expression of MyoD induced by Wnt7a was
reduced (Figs. 2B, E) while Myf5 expression was not, since we
still can see the few Myf5 expressing cells, some of which are
also MyoD positive (Figs. 2D–E and Suppl. Figs. 2M, P, S, N,
Q, T). In explants where myogenesis is induced by Wnt1,
neither Myf5 nor MyoD appear to be reduced (Figs. 2G–H, J–
K, M). We obtained similar results on co-culturing the PSM
explant with neural tube or dorsal ectoderm, instead of Wnt1 or
Wn7a expressing cells respectively (Fig. 2M). JNK inhibitors,
on the other hand, did not have any effect (Figs. 2C, F, I, L, M
and Suppl. Figs. 2O, R, U).
These results indicate that dorsal ectoderm (and Wnt7a)
signals mainly through activation of the PKC pathway. Myf5 is
not strongly activated by this signal but its expression may
account for the residual MyoD expression in the presence ofPKC inhibitors, since MyoD can be directly activated by Myf5
(Tajbakhsh et al., 1997).
We therefore decided to perform similar experiments inMyf5
mutant mice in which early myogenesis is driven only byMyoD.
We dissected presomitic mesoderm (PSM), including dorsal
ectoderm or neural tube fromMyf5nlacZ/nlacZ embryos, which are
null mutant for both Myf5 and Mrf4, or the sibling Myf5nlacZ/+,
orMyf5LoxP/LoxP embryos, in whichMrf4 is still present (Kassar-
Duchossoy et al., 2004). The explant cultures were left to
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MyoD expressing cells in explants of PSM from Myf5nlacZ/nlacZ
embryos in the presence of dorsal ectoderm and treated with
PKC inhibitors are reduced with respect toMyf5nlacZ/+ embryos
(P<0.02, n=8) (Figs. 3C, K, Q; Suppl. Figs. 3Q–V). In
addition in these experiment we were able to test the expression
of β-Galactosidase (β-Gal) as a readout of Myf5 activation
(Figs. 3B, D, F, H, L, N, P, Q). This confirms that while the
neural tube strongly activated β-Gal expression in PSM
explants (Figs. 3F, N, Q), fewer βGal expressing cells were
present in dorsal ectoderm induced explants (Figs. 3B, J, Q).Fig. 3. Myf5 independent myogenesis depends on PKC activity. (A–P) Immunofluo
embryos in the presence of dorsal ectoderm (DE) (A–D, I–L) or neural tube (NT) (E–
of Bisindolylmaleimide I (0.5 μM) (A–B, E–F, I–J, M–N), using antibodies specific
added to control cultures. (Q) Histogram representing the number of Myosin Heavy C
the different culture conditions. Independent experiments (n=8) were performed in tr
represent S.E.M. Bis, Bisindolylmaleimide I (0.5 μM). Scale bar in panels A–P, 10This expression was not affected by the presence of PKC
inhibitors (Figs. 3D, H, L, P Q), suggesting that dorsal ectoderm
signalling leading toMyf5 activation is not PKC dependent. We
observed a similar reduction in MyoD expressing cells in
explants from Myf5LoxP/LoxP embryos when PKC, but not JNK
signalling, was inhibited, in all sets of experiments (Suppl. Fig.
3W and not shown). This shows that Mrf4, is not implicated in
MyoD regulation by the dorsal ectoderm signal. These results
confirm that MyoD expression, induced by the dorsal ectoderm,
is compromised in the absence of activated PKC and that this
effect is even more pronounced in the absence of Myf5.rescence on PSM explants from E9.5 Myf5nlacZ/+ (A–H) or Myf5nlacZ/nlacZ (I–P)
H, M–P), left to differentiate in the presence (C–D, G–H, K–L, O–P) or absence
for Myosin Heavy Chain (MHC), MyoD or β-Galactosidase (Myf5). DMSO is
hain, MyoD or β-Galactosidase positive cells in the single explant cultures under
iplicate and averaged. Double asterisks represent P<0.001 vs. control (C). Bars
0 μm.
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and are involved in MyoD expression
The tissue distribution of different PKC isoforms has only
been partially documented during development (Bogatkevich
et al., 2005; Hamplova et al., 2005; Oehrlein et al., 1998;
Pauken and Capco, 2000; Redling et al., 2004; Wilda et al.,
2001) and we therefore explored whether any particular
isoform was specifically expressed in the PSM, where it
could play a role in the non-canonical pathway leading to
MyoD expression.
We initially assessed the expression of various PKC
isoforms in extracts of the PSM, compared to the total embryo,
at E9.5 by Western blot analysis. As shown in Fig. 4A, PSM
expresses PKCα, β, η, γ, δ, ε, λ at high to detectable levels, the
majority at similar levels to those in the total embryo, except for
α and δ, which appear to be enriched in the PSM. We took
advantage of several newly identified peptides that inhibit
specific PKC isoforms (Disatnik et al., 2002) to investigate
which of the PSM isoforms were mainly responsible for MyoD
expression. We tested inhibitors of PKCβI, βII, γ, ε, and η on
the differentiation of Myf5LoxP/LoxP PSM explants. We also
tested two drugs that show a certain degree of selectivity for
PKCα (Go6976) and PKCδ (rottlerin) (Renault-Mihara et al.,Fig. 4. Several PKC isoforms are expressed in presomitic mesoderm and are
involved in MyoD expression. (A) Western blot analysis on PSM or total
extracts from E9.5 embryos, using PKC antibodies specific for the different
PKC isoforms, PKCα, β, η, γ, δ, ε, λ. (B) Histogram representing the number of
MyoD expressing cells in the PSM explant culture from E9.5 Myf5LoxP/LoxP
embryos differentiated in the presence of the different isoform-specific
inhibitors. Independent experiment (n=8) were performed in triplicate and
averaged. Single cross, single, double and triple asterisks represent P<0.05,
P<0.03, P<0.01 and P<0.001 vs. control (C). Bars represent the S.E.M. C, not
treated control; KI, Kaipharma, classical general PKC inhibitor (1 μM); Bis,
Bisindolylmaleimide I (0.5 μM); Rot, rottlerin PKCδ inhibitor (5 μm), Go,
Go6796, PKCα inhibitor (5 nM), PKCβI, peptide inhibitor of PKCβI; PKCβII,
peptide inhibitor of PKCβII; PKCγ, peptide inhibitor of PKCγ; PKCε, peptide
inhibitor of PKCε; PKC η, peptide inhibitor of PKC η, (all at 1 μM); all,
combination of available PKC inhibitors.2006). While inhibition of PKCβII, γ or ε did not have
significant effects on MyoD expression, we observed that this is
reduced in the presence of selective inhibitors of PKCβI and
η and to some extent by inhibitors that preferentially effect
PKCδ and PKCδ (Fig. 4B). This suggests that, of the isoforms
tested, βI, η, and also possibly α and δ, may be involved in the
transduction of non-canonical Wnt signalling, leading to MyoD
expression.
Inhibition of PKC activity in the PSM alters the
phosphorylation state of many kinases playing a role in
different signal transduction pathways
While the involvement of PKC and, in some instances, the
final transcriptional target of the non-canonical Wnt pathway
has been described in many systems (Jin et al., 2005; Koyanagi
et al., 2005; Pandur et al., 2002a), in the case of somitic
myogenesis it is not known which are the substrates of PKC
phosphorylation and how this signal is transduced.
We thus performed a differential phosphorylation profile
analysis on protein extracts from explants of PSM and dorsal
ectoderm, grown in the presence or absence of PKC inhibitor
for 24 h. The analysis was carried out by the company
KINEXUS using a panel of antibodies specific for phosphosites
(Kinetworks™KPSS-4.1—Phospho-Site) (Fig. 5A, Table 1).
The inhibition of PKC activity in the PSM leads to the
modification of the phosphorylation status of many different
transduction molecules (Figs. 5A–B). Of particular interest is
the decreased phosphorylation of GSK3β, suggesting the
existence of a cross-talk with the β-catenin dependent
pathway, and of p38a MAPK and MKK6, known to be
involved in the regulation of myotome development (De
Angelis et al., 2005). Increased phosphorylation was seen for
ERK1, ERK2, PKCδ and Rb, but the significance of this
remains to be investigated.
Pax3 transcriptional activity, but not Pax3 expression,
is abrogated by PKC inhibitors, and is necessary to initiate
MyoD dependent myogenesis
Pax3 is another key regulator of myogenesis. In the absence
of both Myf5 and Mrf4, MyoD can still be activated. However
the combined mutation in mouse embryos of Myf5, Mrf4 and
Pax3 results in the absence of MyoD activation and the loss
of all skeletal muscles in the trunk and limbs (Kassar-
Duchossoy et al., 2004; Tajbakhsh et al., 1997). It is, however,
still unknown how Pax3 influences MyoD activation. We
therefore decided to investigate whether Pax3 was involved in
the Wnt7A/PKC pathway of MyoD expression. PSM explants
from Pax3GFP/+ embryos were left to differentiate with dorsal
ectoderm, in the presence or absence of PKC inhibitors (Figs.
6A–B and Suppl. Figs. 3A–B). As shown previously, we
observed a reduction of MyoD expression and myogenesis in
the presence of PKC inhibitors (Figs. 6B–C and Suppl. Fig.
6B), while GFP, which reflects expression of Pax3 (Relaix et
al., 2005), was unaffected. The presence of Pax3 protein was
confirmed by Western blot analysis (Fig. 6J): Pax3 is still
Fig. 5. Phosphosite profiling of PSM. (A) Western blot analysis of the phosphorylation status of 40 different phosphoproteins (see Table 1 for the bands position) in
PSM explants from E9.5 embryos co-cultured with dorsal ectoderm, treated (lower gel) or untreated (upper gel) with Bisindolylmaleimide I (0.5 μN) for 24 h, using
antibodies for specific phosphosites. (B) Histogram showing the relative increase or decrease in phosphorylation of the phosphoproteins in Bisindolylmaleimide I (Bis)
treated explants as a percentage of control explants. Only phosphoproteins that gave a positive signal, showing a difference higher than 5% between treated and control
explants are reported here.
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slightly lower. This suggested that in the absence of activated
PKC, the Pax3 protein is unable to activate MyoD.
In order to test the transcriptional activity of Pax3 in this
situation, we performed the same experiment on explants
derived from P34 transgenic embryos, that express the reporter
gene nlacZ driven by a Pax3 responsive element (Relaix et al.,
2004). In these mice the activity of the reporter depends on Pax3
transcriptional activity. We observed a drastic reduction in
nlacZ expression, measured as expression levels of β-
galactosidase, in explants grown in the presence of PKC
inhibitors (Figs. 6D–F and Suppl. Figs. 5C–D). Since Pax3
expression is not affected by these inhibitors, we conclude that
the transcriptional activity of Pax3 requires PKC activity.
A constitutively active form of Pax3, PAX3–FKHR, overcomes
the PKC requirement for MyoD expression
PAX3–FKHR arises in humans as a result of a chromosomal
translocation, t(2;13), which leads to the fusion of the potent C-
terminal transcriptional activation domain of FKHR (FOX01A)
to the N-terminal region of PAX3, which includes the intact
paired-box and homeobox DNA-binding elements. PAX3–
FKHR is a potent gain-of-function mutation and is able to rescue
the Pax3 mutant phenotype (Relaix et al., 2003). We decided to
test whether this activated form of Pax3 was still dependent on
PKC activity, by examining MyoD expression in explants ofPSM and dorsal ectoderm from Pax3PAX3–FKHR–IRESnlacZ/+
embryos, in the presence or absence of PKC inhibitors.
Explants from embryos expressing PAX3–FKHR are able to
express MyoD and differentiate in the presence of PKC
inhibitors (Figs. 6G–I and Suppl. Figs. 6E–F). This therefore
demonstrates that expression of MyoD at this stage depends on
Pax3 transcriptional activity, since PKC inhibition is rescued
by PAX3–FKHR. Pax3 contains several putative consensus
sites for Ser/Thr phosphorylation, amongst which there are 8
sites for PKC, which are conserved in different species (mouse,
human, chicken, xenopus). Pax3 mobility shift on SDS-PAGE
gels is nevertheless not affected when PKC is inhibited by
different inhibitors, but it is when the protein extract is treated
with alkaline phosphatase, indicating that if phosphorylation of
Pax3 is at stake, only a few phosphosites are affected by PKC
(Fig. 6J).
Discussion
PKC, but not β-catenin, is required for MyoD expression at the
onset of myogenesis
Early myogenesis can be triggered by two principal
cascades, initiated by either the axial structures (neural tube
and notochord) or the dorsal ectoderm via signalling molecule
such as the wnts (Wnt1, Wnt3a and Wnt4 or Wnt6 and Wnt7A
respectively) leading to the expression of Myf5 or MyoD in the
Table 1
Legend of the Western blots in Fig. 5A
Lane Band Protein name Abbreviation Epitope ∼MW
2 1 Glycogen synthase
kinase-3 alpha (S21)
GSK3a S21 47
2 2 Glycogen synthase
kinase-3 beta (S9)
GSK3b S9 42
3 1 Protein kinase D
(Protein kinase mu) (S910)
PKCm/PKD S910 134
3 2 Protein kinase C zeta
(T410)/lambda (T403)
PKCz/l T410/403 79
4 1 Unclassified – – 46
4 2 p38 MAPK (T180/Y182) p38a MAPK T180/Y182 39
5 1 90 kDa Ribosomal S6
Kinases (T573/577)
RSK1/2 T573/577 86
5 2 Unclassified – – 81
5 3 Unclassified – – 37
6 1 Protein kinase C alpha/
beta (T638)
PKCa/b T638 79
6 2 Unclassified – – 55
6 3 elF4E binding protein
(S65) (18)
4E-BP1 S65 18
7 1 Retinoblastoma protein
(S807/S811)
Rb S807/S811 115
7 2 90 kDa Ribosomal S6
Kinases (S380/386)
RSK1/2 S380/386 87
8 1 Raf (S259) (70) Raf1 S259 67
8 2 Raf (S259) (60) Raf1 S259 57
8 3 Type1 protein
phosphatase alpha
(T320)
PP1a T320 36
9 1 I-kappa-B kinase beta
(S181)
IKKb S181 86
10 1 Unclassified – – 135
10 2 MKK6(2) (S207) MKK6 S207 33
11 1 Unclassified – – 76
11 2 Protein kinase B (T308) PKBa (Akt1) T308 55
11 3 Unclassified – – 45
12 1 Unclassified – – 72
12 2 MAPK/Erk kinase 1/2
(S217/221)
MEK1/2 S217/221 42
12 3 Unclassified – – 37
13 1 The mammalian target of
Rapamycin (S2448)
mTOR S2448 169
13 2 PKC-related kinase 2
(T816)
PRK2 T816 128
13 3 PKC-related kinase 1
(T774)
PRK1 T774 117
13 4 Unclassified – – 75
13 5 Phosphoinositide-
dependent protein kinase
1 (S244)
PDK1 S244 54
14 1 Protein kinase C delta
(T507)
PKCd T507 71
14 2 Extracellular signal-
regulated kinase 1
(T202/Y204)
ERK1 T202/Y204 43
14 3 Extracellular signal-
regulated kinase 2
(T185/Y187)
ERK2 T185/Y187 41
15 1 Unclassified – – 187
16 1 Unclassified – – 35
16 2 Cyclin-dependent kinase
1 (Y15)
CDK1 Y15 26
17 1 p85 S6 kinase 2
(T444/S447)
S6K2 p85 T444/S447 66
(continued on next page)
Table 1 (continued)
Lane Band Protein name Abbreviation Epitope ∼MW
17 2 p70 S6 kinase
(T421/T424)
S6Ka p70 T421/T424 55
17 3 MAP kinase activated
protein kinase 2 (T334)
MAPKAPK2 T334 43
18 1 Unclassified – – 172
18 2 Retinoblastoma
P rotein (S780)
Rb S780 116
18 3 Unclassified – – 76
19 1 p70 S6 kinase (T389) S6Ka p70 T389 68
19 2 Unclassified – – 37
19 3 Cyclin-dependent
kinase 1 (T161/160)
CDK1 T161/160 25
19 4 Unclassified – – 20
20 1 Lyn (Y507) (46) Lyn Y507 46
611S. Brunelli et al. / Developmental Biology 304 (2007) 604–614mouse embryo (see Cossu et al., 1996; Tajbakhsh et al., 1998).
In the case of Myf5, we recently showed that its epaxial
activation is due to a cooperative interaction between the Wnt/
β-catenin and the Shh/Gli pathways (Borello et al., 2006).
However it remains unknown whether Wnts activate MyoD
through a canonical or a non-canonical pathway. We show here
that Wnt-dependent expression of MyoD can occur indepen-
dently of β-catenin but not of PKC signalling, therefore
demonstrating the implication of a non-canonical Wnt pathway.
The non-canonical Wnt pathway has been described to
regulate many developmental and differentiation processes
(Kohn and Moon, 2005; Medina et al., 2000). In particular, a
PKC dependent non-canonical Wnt pathway has been asso-
ciated with cardiomyogenesis both during Xenopus develop-
ment and more recently in the differentiation of human
circulating progenitor cells (Koyanagi et al., 2005; Pandur et
al., 2002a). Similarly to our findings, inhibition of PKC activity
blocked cardiomyocyte differentiation. An involvement of PKC
in skeletal myogenesis has been demonstrated, at least in
cultured myoblasts and in the cell line C2C12. In contrast to our
results, down-regulation of PKC appeared to be necessary to
allow differentiation and myoblast fusion (Goel and Dey,
2002a,b). However in these experiments PKC appeared not to
mediate Wnt signalling, but probably an insulin or integrin
signalling pathway.
PKC and PKA in the activation of myogenesis
Another kind of non-canonical pathway has been recently
described in muscle progenitor cells in the PSM (Chen et al.,
2005). Wnt1 and Wnt7a potently induce transcription from a
cyclic AMP-responsive element (CRE) promoter. By testing a
barrage of inhibitors and dominant-negative mutants, evidence
is presented that noncanonical Wnt signalling – specifically the
adenylate cyclase (AC) cascade –activates CREB-mediated
transcription and this process is physiologically relevant for
Wnt-induced myogenesis. Increasing AC activity (or elevating
cAMP levels) specifically enhanced expression of MyoD and
Myf5 induced by Wnt1, whereas blocking AC or PKA activity
inhibited both Wnt1- and Wnt7a-mediated myogenesis.
Fig. 6. Pax3 and PKC dependent expression of MyoD. (A–B) Immunofluorescence on PSM explants with dorsal ectoderm from E9.5 Pax3GFP/+ embryos left to
differentiate in the presence of DMSO (A) or of Bisindolylmaleimide I (0.5 μM) (B), using antibodies specific for GFP (green) and MyoD (red). (C) Histogram
representing the number of MyoD or GFP expressing cells in the PSM explant culture from E9.5 Pax3GFP/+ embryos differentiated in the presence or absence of
Bisindolylmaleimide I (0.5 μM). Independent experiment (n=6) were performed in triplicate and averaged. Double asterisks represent P<0.005 vs. control (C). Bars
represent S.E.M. (D–E) Immunofluorescence on PSM explants with dorsal ectoderm, from E9.5 P34 embryos, left to differentiate in the presence or DMSO or
Bisindolylmaleimide I (0.5 μM) (E) of using antibodies specific for β-Galactosidase (β-Gal) (green) andMyoD (red). (F) Histogram representing the number of MyoD
or β-Galactosidase expressing cells in the PSM explant culture from E9.5 P34 embryos differentiated in the presence or absence of Bisindolylmaleimide I (0.5 μM).
Independent experiment (n=5) were performed in triplicate and averaged. Double asterisks represent P<0.005 vs. control (C). Bars represent S.E.M. (G–H)
Immunofluorescence on PSM explants with dorsal ectoderm, from E9.5 Pax3PAX3–FKHR–IRESnlacZ/+ embryos, left to differentiate in the presence of DMSO (G) or of
Bisindolylmaleimide I (0.5 μM) (H), using antibodies specific for β-Gal (green) and MyoD (red). (I) Histogram representing the number of MyoD expressing cells in
the PSM explant culture from E9.5 Pax3PAX3–FKHR–IRESnlacZ/+ embryos differentiated in the presence or absence of Bisindolylmaleimide I (0.5 μM). Independent
experiment (n=5) were performed in triplicate and averaged. Bars represent S.E.M. (J) Western blot analysis of PSM extracts from E9.5 embryos co-cultured with
dorsal ectoderm, untreated (C) or treated with Bisindolylmaleimide I (0.5 μM) (Bis), PKCη inhibitor peptide (1 μm) or in a PSM protein extract dephosphorylated in
vitro with Alkaline Phosphatase (CIP), using antibodies specific for Pax3 and GAPDH. Scale bar in panels A–B, D–E and panels G–H: 100 μm.
612 S. Brunelli et al. / Developmental Biology 304 (2007) 604–614Although these data show that AC activity affects both Myf5
and MyoD, they do not clarify whether either gene may be a
direct target of CREB activity since the experiments were
performed in wild type embryos with both MyoD and Myf5
present at the same time. Likewise, it is not obvious whether
PKA dependent myogenesis occurs independently of the
canonical pathway. Even if it appears that dominant negative
CREB does not affect targets of the canonical pathway (Buttitta
et al., 2003), other data suggest that PKA, by directly
phosphorylating β-catenin, inhibits its ubiquitination, therefore
allowing its accumulation and activating the canonical Wnt
signalling cascade (Hino et al., 2005).
PKC intracellular pathways in myogenesis
How does PKC affect early myogenesis? The data presented
here suggest that several molecules may mediate PKC activity.
Some indications come from the analysis of the phosphorylation
profile of a panel of phosphoproteins in the presence or absence
of PKC activity. We observed that inhibition of PKC activity
leads to a strong modification of the phosphorylation state of
many proteins involved in important signal transduction
pathways. In particular when PKC is inactive, phosphorylation
of MKK6 and p38MAPK are strongly reduced. p38 MAPK
signalling has been implicated in myogenesis with varying
reports of its effects on Myf5 or MyoD expression (De Angeliset al., 2005; Keren et al., 2005; Penn et al., 2004; Wu et al.,
2000).
Inhibition of PKC led to a reduction of GSK3β phosphor-
ylation. Cross-talk between the canonical and non-canonical
Wnt pathways has been described, probably because they share
common components such as Dsh (Kuhl, 2002; Kuhl et al.,
2001) or GSK3β, already identified as a PKC substrate (De
Servi et al., 2005; Oriente et al., 2001). It is possible that during
myogenesis cross-talk exists between the Wnt/PKC pathway
and the Wnt/β-catenin pathway as suggested by the effect of
PKC inhibitors on GSK3β phosphorylation, although in our
PKC inhibition experiments we do not observe detectable
effects on the low level of Myf5 expression in dorsal ectoderm
induced myogenesis.
Pax3 transcriptional activation requires PKC
Another important player in early myogenic induction is
Pax3. Analysis of mutant mice have shown that in the absence
of the myogenic regulatory factors Myf5 and Mrf4, Pax3 is
required for MyoD activation and the entry of cells into the
skeletal muscle programme (Kassar-Duchossoy et al., 2004;
Tajbakhsh et al., 1997). Wnt signalling from the neural tube,
acting through the β-catenin dependent pathway, leads to the
early activation of myogenic regulatory genes, notably Myf5,
which is a direct target of TCF/β-catenin (Borello et al., 2006),
613S. Brunelli et al. / Developmental Biology 304 (2007) 604–614in the epaxial dermomyotome of the somite. In the epaxial
domain, the early expression of MyoD depends on Myf5/Mrf4
(Kassar-Duchossoy et al., 2004; Tajbakhsh et al., 1997). Myf5
and Mrf4 are also transcribed in the hypaxial dermomyotome,
where Pax3 is also strongly expressed. In this domain, MyoD
expression initially depends on Myf5/Mrf4 but this is also
transitory and indeed in the explant experiments reported here
only a small additional effect was observed using Myf5/Mrf4
mutant embryos.
Wnt signalling from the dorsal ectoderm is probably most
important for myogenesis in this hypaxial context, and also
potentially for the Pax3/Pax7 positive progenitor cells derived
from the central region of the dermomyotome of the mouse
embryo (Relaix et al., 2005). In the Myf5/Mrf4 double mutant,
there is a minor delay in early MyoD activation in the hypaxial
domain (Tajbakhsh et al., 1997). The results reported here
demonstrate that non-canonical Wnt signalling regulates MyoD
expression in a Pax3-dependent manner, since in the presence of
this transcription factor, MyoD expression is downregulated by
PKC inhibitors, whereas in the presence of PAX3–FKHR it is
not. Furthermore this observation provides insight into the way
PKC affects Pax3 activity. Pax3 itself is a poor transcriptional
activator and probably requires a co-activator or modifications
in order to act efficiently (Relaix et al., 2003). PAX3–FKHR,
which has the strong activation domain of FKHR circumvents
this requirement. We identify several potential phosphorylation
sites for PKC in the Pax3 protein, which are conserved in other
species. No detectable change in size is seen for Pax3, on the
basis of electrophoretic mobility, in the presence of PKC
inhibitors, however this may reflect the large number of
phosphorylated residues, since a size change is detected on
electrophoresis only after global dephosphorylation. Alterna-
tively, or in addition, co-activator phosphorylation may be
involved; we are currently looking for Pax3 interacting proteins
in the myogenic context. We favour this explanation since Pax3
can also activate Myf5, probably through a different PKC-
independent co-activator (Bajard et al., 2006). Wnt signaling
has been implicated in the maintenance of Pax3 expression in
pre-somitic mesoderm (Fan et al., 1997). Canonical Wnts such
as Wnt1 derived from the neural tube have more effect than
dorsal ectoderm derived Wnts such as Wnt6 although both
signalling pathways act on Pax3. This represents a further level
of regulation, in addition to that exerted by PKC dependent Wnt
signalling from the dorsal ectoderm on Pax3 activity. Indeed the
latter may affect Pax3 transcription through an autoregulatory
feedback loop. In Pax3nlacZ/nlacZ mice we continue to see β-
galactosidase positive cells (Relaix et al., 2004), indicating that
Pax3 is not essential for at least some level of Pax3
transcription. Indeed in the presence of PKC inhibitors, Pax3
is still present, although slightly reduced.
In conclusion, we have provided new insights into the
complex regulatory network that drives the early phases of
embryonic myogenesis. We demonstrate that MyoD expression
can occur in the absence of an active Wnt/β-catenin pathway,
through a Wnt/PKC non-canonical pathway. We show that
expression of MyoD is mainly Pax3 dependent and that Pax3
transcriptional activity is modulated by PKC, directly orindirectly by phosphorylation of the factor itself or putative
co-factors. In addition we provide some insight into how
activation of PKC by Wnt may act on the signal transduction of
other signalling pathways, including the Wnt/β-catenin cano-
nical pathway.
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